Yousif Capital Management LLC Sells 1,203 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Yousif Capital Management LLC lessened its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.3% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 27,085 shares of the pharmaceutical company’s stock after selling 1,203 shares during the quarter. Yousif Capital Management LLC’s holdings in Vertex Pharmaceuticals were worth $10,907,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Northwest Investment Counselors LLC bought a new position in Vertex Pharmaceuticals during the 3rd quarter worth approximately $25,000. Highline Wealth Partners LLC bought a new position in Vertex Pharmaceuticals in the third quarter worth about $27,000. Dunhill Financial LLC lifted its position in Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 24 shares during the period. Brown Lisle Cummings Inc. bought a new stake in Vertex Pharmaceuticals in the fourth quarter worth $30,000. Finally, Legacy Investment Solutions LLC purchased a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $33,000. Institutional investors own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

VRTX has been the subject of several analyst reports. HC Wainwright upped their price objective on Vertex Pharmaceuticals from $535.00 to $550.00 and gave the stock a “buy” rating in a research note on Friday, January 31st. JPMorgan Chase & Co. lowered their target price on Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating for the company in a research report on Monday, December 23rd. Morgan Stanley boosted their target price on Vertex Pharmaceuticals from $473.00 to $476.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Jefferies Financial Group upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the company from $500.00 to $550.00 in a research report on Monday, December 9th. Finally, Canaccord Genuity Group raised their target price on shares of Vertex Pharmaceuticals from $361.00 to $408.00 and gave the stock a “sell” rating in a research report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $502.58.

Vertex Pharmaceuticals Stock Up 1.3 %

Shares of VRTX stock opened at $488.44 on Thursday. The firm has a market capitalization of $125.79 billion, a PE ratio of -245.45, a P/E/G ratio of 2.39 and a beta of 0.41. The stock’s 50-day simple moving average is $435.03 and its 200-day simple moving average is $462.56. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.69 billion. During the same quarter last year, the company earned $3.67 EPS. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post -1.93 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.